文献速递淋巴瘤

利妥昔单抗时代第一个十年内滤泡性淋巴瘤的死因:法国与美国队列的汇总分析

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
PubMed 文献 · J Clin Oncol · 2018-11-27

该汇总分析纳入法国两家转诊机构2001至2013年新诊断的734例和美國University of Iowa与Mayo Clinic SPORE 2002至2012年新诊断的920例滤泡性淋巴瘤1-3A级患者,中位随访分别为89个月和84个月。法国队列10年总生存率为80%,美国队列为77%。在283例死亡者中可分类死因者248例(88%),淋巴瘤是最常见死因,10年累积发生率为10.3%,其次为治疗相关死亡(3.0%)、其他恶性肿瘤(2.9%)、其他原因(2.2%)和未知(3.0%)。结论认为尽管总生存改善,淋巴瘤仍是主要死因,尤其在疾病转化后,治疗相关死亡也值得关注,支持需要毒性更低的治疗。

要点

  • 淋巴瘤是滤泡性淋巴瘤最常见死因,10年累积发生率为10.3%。
  • 治疗相关死亡10年累积发生率为3.0%,其他恶性肿瘤为2.9%。
  • 诊断后24个月内未达到无事件生存者,淋巴瘤或治疗相关死亡10年累积发生率为36.1%,高于其他原因死亡的7.0%。

核心结论

  • 尽管利妥昔单抗时代滤泡性淋巴瘤总生存改善,淋巴瘤仍是主要死因,尤其在疾病转化后;治疗相关死亡也值得关注,支持需要毒性更低的治疗。

研究设计与样本

  • 汇总两个新诊断滤泡性淋巴瘤1-3A级队列:法国两家转诊机构2001至2013年纳入734例,中位随访89个月;美国University of Iowa与Mayo Clinic SPORE 2002至2012年纳入920例,中位随访84个月。

主要发现

  • 10年总生存率法国队列为80%,美国队列为77%。
  • 283例死亡者中可分类死因者248例(88%);总体队列淋巴瘤10年累积发生率为10.3%,治疗相关死亡为3.0%,其他恶性肿瘤为2.9%,其他原因为2.2%,未知为3.0%。
  • 诊断时年龄≥70岁组淋巴瘤或治疗相关死亡10年累积发生率为25.4%,其他原因死亡为16.6%。
  • 滤泡性淋巴瘤国际预后指数(FLIPI)评分3至5组淋巴瘤或治疗相关死亡10年累积发生率为27.4%,其他原因死亡为5.2%;FLIPI评分0至1组分别为4.0%和3.7%。
  • 诊断后24个月内未达到无事件生存组淋巴瘤或治疗相关死亡10年累积发生率为36.1%,其他原因死亡为7.0%;达到无事件生存组分别为6.7%和5.7%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. PATIENTS AND METHODS: We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. RESULTS: Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. CONCLUSION: Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sarkozy C, Maurer MJ, Link BK, et al. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol. 2018. PMID: 30481079. doi:10.1200/JCO.18.00400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。